《大行》大华继显降国药(01099.HK)评级至“沽售” 首九月业绩逊

阿斯达克财经
Oct 29, 2024

大华继显发表报告,认为国药(01099.HK) 今年首9个月业绩欠佳,收入及盈利均低于预期。虽然低利率环境有助公司降低财务成本,但政策不确定性以及经济疲弱可能会继续影响公司2024年至2026年的盈利增长能见度,因此将其评级降至“沽售”,目标价由20元降至18元。报告将国药今年盈利预测,由按年下降7.3%调整至下跌13%,以反映利润率显著下降以及具挑战性的商业环境。大华继显亦指,国药亦面临政策变化...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10